D. E. Shaw & Co., Inc. Unity Biotechnology, Inc. Transaction History

D. E. Shaw & Co., Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.72 - $1.86 $7,309 - $18,882	-10,152 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.3 - $3.17 $136,843 - $333,686	-105,264 Reduced 91.2%	10,152 $15,000
Q3 2021 Nov 15, 2021	BUY	$2.91 - $4.5 $175,507 - $271,404	60,312 Added 109.45%	115,416 $346,000
Q2 2021 Aug 16, 2021	BUY	$4.15 - $6.3 $228,681 - $347,155	55,104 New	55,104 $256,000
Q1 2021 May 17, 2021	SELL	$5.51 - $9.42 $85,652 - $146,433	-15,545 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.42 - $6.36 $53,163 - $98,866	15,545 New	15,545 $81,000
Q3 2020 Nov 16, 2020	SELL	$2.94 - $12.43 $45,858 - $193,883	-15,598 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.28 - $9.67 $82,357 - $150,832	15,598 New	15,598 $135,000
Q1 2020 May 15, 2020	SELL	$5.0 - $7.6 $173,570 - $263,826	-34,714 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.99 - $8.38 $207,936 - $290,903	34,714 New	34,714 $250,000
Q4 2018 Feb 14, 2019	SELL	$10.76 - $17.25 $120,684 - $193,476	-11,216 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.34 - $22.97 $160,837 - $257,631	11,216 New	11,216 $183,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $14M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.